logo-loader

Milestone Scientific receives Notice of Allowance from US patent office for new CompuPulse system

Published: 15:35 24 Feb 2021 EST

Milestone Scientific Inc -
Shares of Milestone were up around 8% in Wednesday afternoon trading to sit at $4

Milestone Scientific Inc (NYSEAMERICAN:MLSS) announced Wednesday it had received a Notice of Allowance from the US patent office for its new CompuPulse System.

The CompuPulse System integrates Milestone’s CompuWave technology with a manual syringe, and the Notice of Allowance relates to a method and apparatus that detects a pulsatile pressure waveform to more easily perform the identification of anatomical target regions.

In a statement, Mark Hochman, Milestone’s clinical director and the inventor of the technology, said the system combines the benefits of CompuWave technology with a manual syringe.

READ: Milestone Scientific begins sales of CompuFlo epidural instruments and disposables to University Hospital of Wurzburg

“(The) new CompuPulse System allows one to identify a pulsatile pressure waveform in a variety of applications, thereby improving the reliability and safety of a drug delivery procedure,” Hochman said. “Importantly, not all procedures require the sophistication of our CompuFlo system, which precisely controls the administration and flow rate of medication as it is being administered. This new technology provides an efficient and low cost alternative for procedures where a manual syringe may suffice, while still providing the ability to verify needle and subsequent catheter placement.”

According to New Jersey-based Milestone, the pulsatile waveform is representative of the detection of pressures that are produced by the cardio-vascular system either directly or indirectly. This same system can be used to aid in the determination of the patency of a catheter and to assist in determining if a catheter has been displaced during a procedure.

The Notice of Allowance significantly expands the intellectual property surrounding its injection and drug delivery systems and further solidifies Milestone’s leadership position in the computerized injection market, interim CEO Leonard Osser told investors.

“We believe that the combination of the CompuWave technology with the lower cost of a manual syringe opens up a number of exciting new markets and applications for our technology, while still ensuring precise confirmation of needle placement and verification that a catheter has not been displaced during or after a procedure.”

Milestone Scientific is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications.

Shares of Milestone were up around 8% in Wednesday afternoon trading to sit at $4.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

15 minutes ago